Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.35 |
| ▸ | METAP2 | P50579 | 4/20 | 0.34 |
| ▸ | METAP1 | P53582 | 4/20 | 0.34 |
| ▸ | CIT | O14578 | 2/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 3/20 | 0.31 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449686 | 0.83 | SMN1; SMN2 (0.45) | METAP2METAP1CIT | |
| SCHEMBL266063 | 0.82 | CTSS (0.43) | TDP1CTSSCTSLCTSK | |
| SCHEMBL1449009 | 0.82 | CIT (0.35) | AAK1METAP2METAP1CIT | |
| SCHEMBL1449614 | 0.80 | TDP1 (0.52) | METAP2METAP1TDP1CTSS | |
| SCHEMBL1449052 | 0.78 | ALDH1A1 (0.44) | AAK1METAP2METAP1 | |
| SCHEMBL1449034 | 0.77 | CTSL (0.47) | METAP2METAP1CTSSCTSLCTSK | |
| SCHEMBL1449065 | 0.76 | AAK1 (0.37) | AAK1METAP2METAP1TDP1CTSS | |
| SCHEMBL5573504 | 0.74 | METAP2 (0.34) | AAK1METAP2METAP1CITCTSC | |
| SCHEMBL2492378 | 0.72 | CTSS (0.37) | TDP1CTSSCTSLCTSK | |
| Hydrochloric Acid SCHEMBL266603 | 0.71 | GAA (0.43) | METAP2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910556-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20090131330-A1 | PAR-2 AGONIST | KOWA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845104-A1 | PAR-2 AGONIST | Kowa Company. Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131330-A1 | PAR-2 AGONIST | F2RL1, CNR2, FFAR2 | AAK1 1179/4885METAP2 564/4885METAP1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.